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lines	 the	 importance	 of	 cancer	 surveillance	 programs	 and	 assessment	 of	 mental	
health	in	the	standard	of	care	in	adolescent	pIBD	patients.
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1  | INTRODUC TION
The	 incidence	of	 cancer	 and	mortality	 in	 IBD	has	been	extensively	






The	 few	 population‐based	 cancer	 studies	 that	 include	 su-
banalyses	 on	 paediatric	 onset	 IBD	 (pIBD)	 have	 found	 an	 overall	
two‐three	 fold	 increased	 risk	 of	 cancer.2,7,8	 In	 the	 paediatric	 lit-
erature	on	malignancy	in	IBD,	only	two	population‐based	studies	
exist.	One	of	 these	reported	a	25‐fold	 increase	 in	CRC	 in	paedi-
atric	 onset	 ulcerative	 colitis	 (pUC),	 but	 this	 study	 included	 only	
69	 patients	 of	whom	 two	 developed	CRC.9	 The	 last	 and	 largest	
study	 in	 pIBD,	 a	 nation‐wide	 study	 from	Sweden,	 demonstrated	
a	 twofold	 increase	 in	cancer	 in	general	and	a	18‐fold	 increase	 in	
gastro‐intestinal	cancers.10
Regarding	mortality,	the	risk	of	death	in	IBD	seems	to	be	declin-













ject	 is	 primarily	 derived	 from	 studies	 performed	 in	 a	 single	 study	
cohort	(the	two	nationwide	Swedish	studies10,13).	Hence,	we	aim	to	
estimate	the	risk	of	cancer	and	mortality	in	pIBD	diagnosed	in	two	
more	 recent	 nationwide	 population‐based	 cohorts	 from	Denmark	
and Finland.












In	 both	 Danish	 and	 Finnish	 registries,	 IBD	 was	 defined	 as	
International	Classification	of	Diseases	eight	revision	(ICD‐8)	codes	






We	considered	 the	diagnosis	 as	 valid	 if	 two	or	more	entries	were	





any	 cancer	 in	 Denmark	 (including	 exact	 diagnosis	 and	 date	 of	 di-




In	Finland,	 the	pIBD	cohort	was	 identified	 through	 the	Special	
Reimbursement	Registry	which	is	maintained	by	the	Social	Insurance	
Institution	of	Finland.	This	registry	includes	data	on	diagnosis	of	all	
patients	 eligible	 for	 special	 reimbursement	 of	 medical	 expenses,	
including	 IBD.	This	 registry	has	previously	been	shown	 to	have	an	
excellent	coverage	and	validity	and	has	been	used	 to	estimate	 the	
incidence	of	pIBD	in	Finland.15-17	The	pIBD	cohort	was	crosslinked	
to	the	National	 Institute	for	Health	and	Welfare	 (THL),	 the	Cancer	








In	both	countries,	we	used	 the	 last	 recorded	diagnosis	code	 in	
the	 registries	 as	 the	 valid	 diagnosis.	 The	 age‐specific	 cancer	 rates	








diagnosis	 or	 death	 on	 31	December	 2014,	whichever	 event	 came	
first.	When	 estimating	 the	 risk	 of	 CRC,	 only	 person‐years	 before	
colectomy	were	considered	time	at	risk.
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The	overall	differences	 in	cancer	and	mortality	 risks	between	
the	 pIBD	 cohorts	 and	 the	 general	 population	 were	 calculated	
using	 standardised	 incidence	 ratios	 (SIR)	 and	 standardised	 mor-
tality	ratios	(SMR).	Among	the	pIBD	patients,	the	numbers	of	ob-
served	cases	and	person‐years	at	risk	were	calculated	by	sex	and	





and	calendar	period	 in	 the	background	population	of	 the	 respec-
tive	 countries.	To	 calculate	SIR	or	SMR,	 the	observed	number	of	
cases	was	divided	by	the	expected	number.	For	SIR	and	SMR,	the	









From	1992	 to	 2015	we	 identified	 6,689	 patients	with	 pIBD.	Of	







presented	 in	 Table	 S1.	 Total	 follow‐up	 time	 of	 the	 pIBD	 cohort	
was	71	675	person‐years,	with	37	830	person‐years	 in	Denmark	





a	 total	 colectomy	performed	with	a	median	 time	 from	diagnosis	
to	colectomy	of	2.8	years	(IQR:	1.0‐6.1).	A	total	of	1,365	patients	













In	 CD,	 the	 overall	 cancer	 incidence	was	 10.7/	 10	000	 person‐
years	 and	 the	 SIR	was	 2.6	 (CI:	 1.8‐3.7).	 The	 country	 specific	 inci-










Total 6689 2921 3741
Male 3544 1648 1882










Cancer	cases	(n) 72 33 39
Deaths	(n) 65 21 44
CD,	Crohn's	disease;	IBD,	inflammatory	bowel	disease;	IQR,	interquartile	
range;	UC,	ulcerative	colitis.






Total 72 33 39
Male 37 15 22








Total 65 21 44
Male 39 16 23





CD,	 Crohn's	 disease;	 IBD,	 inflammatory	 bowel	 disease;	 UC,	 ulcerative	
colitis.
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years	 in	Denmark	 and	 10.6/	 10	000	 patient	 years	 in	 Finland.	 The	
overall	 (all	cause)	SMR	was	3.0	 (CI:	2.4‐3.9)	and	the	cause	specific	
mortalities	are	presented	in	Table	4	with	the	country	specific	mor-
talities	 presented	 in	 Table	 S4.	 The	median	 time	 from	diagnosis	 to	
mortality	 was	 9.4	years	 (range:	 0.01‐22.4)	 and	 the	 median	 age	
at	 mortality	 was	 22.0	years	 (range:	 8‐35).	 The	 leading	 causes	 of	
mortality	were	 cancer	 (one	 in	4008	patient	 years),	 suicide	 (one	 in	












In	 this	 nationwide	 population‐based	 study	 from	 Denmark	 and	
Finland,	we	 followed	 pIBD	 patients	 from	 IBD	 diagnosis	 to	 cancer	




All 2.5	(2.0‐3.2) 2.6	(1.8‐3.7) 2.5	(1.8‐3.4)
Colorectal	cancers 15.3	(8.7‐24.8) 8.4	(2.3‐21.4) 21.4	(11.0‐37.4)
Small	bowel	cancers 21.8	(4.4‐63.6) 32.6	(3.7‐117.8) 13.3	(0.2‐74)
Liver	cancers 42.8	(19.5‐81.3) 21.8	(2.5‐78.9) 59.5	(23.8‐122.6)
Lymphomas 2.9	(1.4‐5.3) 3.2	(1.0‐7.6) 2.6	(0.8‐6.0)
Skin	cancers 4.2	(2.4‐6.7) 6.7	(3.4‐11.6) 2.2	(0.7‐5.2)
Number	of	cancer	cases	(n)
Gastrointestinal
Colorectal	cancer 16 4 12
Small	bowel	cancer 3 2 1
Liver	cancers
Cholangiocarcinoma 8 1 7
Hepatocellular	carcinoma 1 1 0
Lymphomas
Hodgkin's	lymphoma 7 4 3
Non‐Hodgkin's	lymphoma 3 1 2
Skin	cancer
Malignant	melanoma 10 7 3
Basal	cell	carcinoma 7 5 2
Non‐IBD	related	cancers
Genital	cancers 6 4 2
Sarcoma 3 1 2
Adrenal	tumour 1 0 1
Mucoepidermoid	carcinoma 1 1 0
Haematologic	cancers 2 1 1
CNS	tumour 4 2 2
CD,	Crohn's	disease;	CI,	confidence	interval;	IBD,	inflammatory	bowel	disease;	UC,	ulcerative	colitis.




an	 increased	frequency	of	colorectal	adenocarcinomas	 (CRC),	 liver	
cancers,	skin	cancers	and	lymphomas	and	the	median	age	of	cancer	






in	 the	 recent	nationwide	Swedish	pIBD	study10	 and	 twice	 the	 risk	
estimate	 reported	 in	 the	 recent	adult	 literature.7,21	 In	 the	Swedish	
study	 they,	however,	 reported	an	almost	20‐fold	 increased	 risk	of	
developing	CRC	which	is	higher	than	the	15‐fold	increased	risk	re-










cholangitis	 (PSC)	cohort	 from	Sweden,	 in	which	79%	had	 IBD,	 the	
risk	of	cholangiocarcinoma	was	reported	to	be	160‐fold	increased,	








We	 found	 three	 cases	 of	 small	 bowel	 carcinomas	 (SBC)	 in	 the	
Finnish	 population	 (age	 at	 cancer	 diagnosis:	 22‐33	years.	 Year	 of	
diagnosis:	2003‐2014).	The	 risk	of	SBC	has	also	been	 found	 to	be	
increased	 in	 coeliac	disease,24	which	may	be	 associated	with	 IBD.	
Hence,	it	remains	unknown	if	the	increased	SIR	of	SBC	is	explained	




Due	 to	 the	 immunosuppressant	 effects	 of	 both	 immunomod-
ulators	 and	 biologicals,	 IBD	 patients	 are	 considered	 to	 be	 at	 an	
increased	 risk	 of	 lymphoproliferative	 diseases	 (primarily	 lympho-
mas).25	 Two	 tertiary	 centre	 studies	 found	 that	 pIBD	 patients	 had	
an	 increased	 risk	 lymphoproliferative	 diseases	 when	 treated	 with	
thiopurines.26,27	The	only	population‐based	study	report	on	lymph-
oproliferative	diseases	 in	pIBD	found	a	2.7	times	 increased	risk	of	




















We	 found	 a	 threefold	 increase	 in	 the	 standardised	 mortal-












The	other	 important	cause	of	mortality	 (besides	cancer)	 in	our	
study,	 was	 infections.	 This	 is	 in	 line	 with	 two	 previous	 European	
multicentre	 studies	 and	 a	 systematic	 review	 reporting	 on	 cancer	
and	mortality	in	pIBD.12,32,33	However,	these	studies	where	mainly	





All 3.0	(2.4‐3.9) 2.2	(1.4‐3.4) 3.7	(2.7‐5.0)
Suicide 3.8	(2.2‐6.0) 2.8	(1.0‐6.2) 4.6	(2.4‐8.0)
Cause	specific	mortality	(n)
Cancer 18 3 15
Infections 11 3 8
Suicide 18 6 12
Gastrointestinal 2 2 0
Other 16 7 9
CD,	Crohn's	 disease;	CI,	 confidence	 interval;	 IBD,	 inflammatory	bowel	
disease;	UC,	ulcerative	colitis.
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case	based	and	 the	 systematic	 review	 is	primarily	based	on	 those	
two	studies.
The	strength	of	 this	study	 is	 the	nationwide	design	with	 inclu-






















possibility	 to	 verify	 the	 data	 in	 patient	 charts.	However,	with	 the	





mortality	 in	 pIBD	with	 cancer	 presentation	 from	 the	 late	 teens	
and	early	adulthood.	This	adds	to	the	mounting	evidence34‐36	that	
pIBD	 is	 a	 distinct	 IBD	 phenotype	 and	 should	 be	 appreciated	 as	
a	 disease	 modifier	 predicting	 a	 more	 aggressive	 disease	 course	
compared	 to	adult	onset	 IBD.	Moreover,	 the	number	of	 suicides	
was	 alarming,	 warranting	 attention	 to	 the	 mental	 health	 of	 the	
patients.	Lastly,	 this	study	highlights	 the	need	for	 future	studies	
designed	to	estimate	possible	risk	factors	of	cancer	development	
in	pIBD.	This	would	facilitate	the	design	of	an	evidence‐based	can-
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